BioSpace News Archive

Biotech Beach

MabVax Therapeutics Schedules Previously Announced 1-for-3 Reverse Stock Split to Regain Compliance with NASDAQ’s $1.00 Minimum Bid Price Maintenance Requirement

There is no guarantee that the Company will successfully regain compliance.

February 15, 2018

·

6 min read

Drug Development

Arrowhead Receives Regulatory Clearance to Begin Phase I/II Study of ARO-HBV for Treatment of Hepatitis B

The company anticipates that dosing will begin around the end of March.

February 15, 2018

·

3 min read

Astellas and Universal Cells Ink $124M R&D Pact fo

Business

GT Biopharma Promotes COO to Top Post, Effective Immediately

Mr. Cross has held the position of President and COO of GTBP since November 16, 2017.

February 15, 2018

·

5 min read

Genetown

Tremeau Completes $5.2M Equity Raise to Fund Non-Opioid Pain Treatments for Rare Diseases

The funding will be used to advance Tremeau’s pipeline of non-opioid pain treatment candidates.

February 15, 2018

·

4 min read

Policy

DreaMed Diabetes Receives CE Mark for Platform for the Management of Type 1 Diabetes

DreaMed Diabetes’ cloud-based solution achieved similar glycemic control to that of medical experts in pilot studies, while simplifying patient experience, by offering a personalized insulin treatment plan based on the analysis of vast amounts of data from a variety of sources.

February 15, 2018

·

4 min read

Business

Evotec and MaRS Innovation Announce First Funded Project under LAB150 Bridge

The project aims to develop kallikrein-targeting compounds as novel topical drugs for the rare but severe inflammatory skin disease ‘Netherton Syndrome’ as well as the broader disorder atopic dermatitis.

February 15, 2018

·

5 min read

Deals

BD Completes Asset Divestitures to Merit Medical

The completion of the divestitures satisfies the remaining contingencies within the previously received regulatory approvals in the U.S., Europe and China for BD’s acquisition of C. R. Bard which was completed on Dec. 29, 2017.

February 15, 2018

·

1 min read

Business

Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017

AMPYRA (dalfampridine) Extended Release Tablets, 10 mg - For the quarter ended December 31, 2017, the Company reported AMPYRA net revenue of $167.2 million compared to $132.3 million for the same quarter in 2016.

February 15, 2018

·

18 min read